Capricor Therapeutics Shares Rise Following FDA Update on Deramiocel Application
Capricor Therapeutics (NASDAQ:CAPR) shares rose by 2.5% in pre-market trading to $10.16, following an August update from the U.S. Food and Drug Administration regarding a revised biologics license application for deramiocel. The FDA indicated it would review the amendment focused on preserving upper-limb function in Duchenne muscular dystrophy patients after previously rejecting the original cardiomyopathy indication. On August 14, Cantor Fitzgerald upgraded Capricor to 'Overweight' and raised its price target from $3.50 to $28, citing the FDA's willingness to review the revised application and new data from the HOPE-3 study. The company reported holding approximately $237.9 million in cash as of Q2 2026, sufficient for at least a year of operations. Capricor is awaiting an FDA decision on deramiocel with a PDUFA target date set for November 22, 2026.
Tickers: $CAPR
Topics: biotech CAPR stock deramiocel fda_review